Management of Inherited Bleeding Disorders in Pregnancy (Green-top Guideline No. 71)
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Это руководство предназначено как для специалистов-гематологов, так и для акушеров, которые имеют опыт ведения беременных с нарушениями свертываемости крови. Кроме того, эти рекомендации могут быть полезными для анестезиологов в акушерстве и неонатологов. Женщины, унаследовавшие нарушения свертываемости крови, могут подвергаться значительному риску кровотечения после выкидышей, абортов, дородовых процедур и родов. Они требуют индивидуального мультидисциплинарного специализированного ухода с перекрестной коммуникацией специалистов, в том числе анестезиологов и неонатологов при необходимости. Был достигнут прогресс в выявлении акушерских проблем у этих женщин и повышении уровня осведомленности об оказании медицинской помощи среди работников здравоохранения. Конкретные аспекты их ведения в акушерстве включают консультирование на этапе преконцепционной подготовки, пренатальную диагностику (ПНД), антенатальный, внутриутробный и послеродовой уход и немедленную помощь новорожденному.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002;55:127–44.
Wacey AI, Tuddenham EG. Mutation databases on the Web. J Med Genet 1998;35:529–33. http://dx.doi.org/10.1136/jmg.35.7.529
de Brasi C, El‐Maarri O, Perry DJ, Oldenburg J, Pezeshkpoor B, Goodeve A. Genetic testing in bleeding disorders. Haemophilia 2014;20 Suppl 4:54–8. https://doi.org/10.1111/hae.12409
Kasper CK, Lin JC. Prevalence of sporadic and familial haemophilia. Haemophilia 2007;13:90–2. https://doi.org/10.1111/j.1365-2516.2006.01397.x
Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, et al. Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010;149:498–507. https://doi.org/10.1111/j.1365-2141.2010.08139.x
Miesbach W, Alesci S, Geisen C, Oldenburg J. Association between phenotype and genotype in carriers of haemophilia A. Haemophilia 2011;17:246–51. https://doi.org/10.1111/j.1365-2516.2010.02426.x
Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8:1256–65. https://doi.org/10.1111/j.1538-7836.2010.03823.x
Plug I, Mauser‐Bunschoten EP, Bröcker‐Vriends AH, van Amstel HK, van der Bom JG, van Diemen‐Homan JE, et al. Bleeding in carriers of hemophilia. Blood 2006;108:52–6. https://doi.org/10.1182/blood-2005-09-3879
Renault NK, Dyack S, Dobson MJ, Costa T, Lam WL, Greer WL. Heritable skewed X‐chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur J Hum Genet 2007;15:628–37. https://doi.org/10.1038/sj.ejhg.5201799
Orstavik KH, Scheibel E, Ingerslev J, Schwartz M. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Thromb Haemost 2000;83:433–7. https://doi.org/ 10.1055/s-0037-1613833
Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia 2008;14:56–64. https://doi.org/10.1111/j.1365-2516.2007.01561.x
Sachs BP, Acker D, Tuomala R, Brown E. The incidence of symptomatic intracranial hemorrhage in term appropriate‐for‐gestation‐age infants. Clin Pediatr (Phila) 1987;26:355–8. https://doi.org/10.1177/000992288702600706
Hanigan WC, Powell FC, Miller TC, Wright RM. Symptomatic intracranial haemorrhage in full‐term infants. Childs Nerv Syst 1995;11:698–707. https://doi.org/10.1007/BF00262235
Towner D, Castro MA, Eby‐Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999;341:1709–14. https://doi.org/10.1056/NEJM199912023412301
Hughes CA, Harley EH, Milmoe G, Bala R, Martorella A. Birth trauma in the head and neck. Arch Otolaryngol Head Neck Surg 1999;125:193–9. https://doi.org/10.1001/archotol.125.2.193
Mosavat SA, Zamani M. The incidence of birth trauma among live born term neonates at a referral hospital in Rafsanjan, Iran. J Matern Fetal Neonatal Med 2008;21:337–9. https://doi.org/10.1080/14767050801927921
Ljung RC, Sjörin E. Origin of mutation in sporadic cases of haemophilia A. Br J Haematol 1999;106:870–4. https://doi.org/10.1046/j.1365-2141.1999.01631.x
Yoffe G, Buchanan GR. Intracranial hemorrhage in newborn and young infants with hemophilia. J Pediatr 1988;113:333–6. https://doi.org/10.1016/S0022-3476(88)80277-4
Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz‐Körholz C, Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs‐‐a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 1999;158 Suppl 3:S162–5. https://doi.org/10.1007/PL00014346
Revel‐Vilk S, Golomb MR, Achonu C, Stain AM, Armstrong D, Barnes MA, et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr 2004;144:490–5. https://doi.org/10.1016/j.jpeds.2003.12.016
MacLean PE, Fijnvandraat K, Beijlevelt M, Peters M. The impact of unaware carriership on the clinical presentation of haemophilia. Haemophilia 2004;10:560–4. https://doi.org/10.1111/j.1365-2516.2004.00955.x
Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007;13:380–2. https://doi.org/10.1111/j.1365-2516.2007.01492.x
Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al.; Haemophilia Treatment Center Network Investigation. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009;15:1281–90. https://doi.org/10.1111/j.1365-2516.2009.02074.x
Kenet G, Chan AKC, Soucie JM, Kulkarni R. Bleeding disorders in neonates. Haemophilia2010;16 Suppl 5:168–75. https://doi.org/10.1111/j.1365-2516.2010.02316.x
Richards M, Lavigne Lissalde G, Combescure C, Batorova A, Dolan G, Fischer K, et al.; European Haemophilia Treatment and Standardization Board. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012;156:374–82. https://doi.org/10.1111/j.1365-2141.2011.08967.x
Davies J, Kadir RA. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta‐analysis of the literature. Haemophilia 2016;22:32–8. https://doi.org/10.1111/hae.12726
Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M; Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011;154:208–15. https://doi.org/10.1111/j.1365-2141.2010.08545.x
Kulkarni R, Ponder KP, James AH, Soucie JM, Koerper M, Hoots WK, et al. Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia 2006;12:205–11. https://doi.org/10.1111/j.1365-2516.2006.01277.x
Maternal obesity and maternal health. Accessed 2015 Oct 7. www.noo.org.uk/NOO_about_obesity/maternal_obesity/maternalhealth
NHS England. Clinical Commissioning Policy: Pre‐implantation Genetic Diagnosis (PGD). Leeds: NHS England, 2014. Accessed 2016 Jun 15.
Fernández RM, Peciña A, Sánchez B, Lozano‐Arana MD, García‐Lozano JC, Pérez‐Garrido R, et al. Experience of preimplantation genetic diagnosis for hemophilia at the University Hospital Virgen Del Rocío in Spain: technical and clinical overview. Biomed Res Int 2015;2015:406096. https://doi.org/10.1155/2015/406096
Kadir RA, Sabin CA, Goldman E, Pollard D, Economides DL, Lee CA. Reproductive choices of women in families with haemophilia. Haemophilia 2000;6:33–40. https://doi.org/10.1046/j.1365-2516.2000.00353.x
Tengborn L, Blombäck M, Berntorp E. Tranexamic acid‐‐an old drug still going strong and making a revival. Thromb Res 2015;135:231–42. https://doi.org/10.1016/j.thromres.2014.11.012
Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Brit J Haematol 1981;47:283–93. https://doi.org/10.1111/j.1365-2141.1981.tb02789.x
Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003;1:682–9. https://doi.org/10.1046/j.15387836.2003.00190.x
Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia 2014;20:158–67. https://doi.org/10.1111/hae.12254
Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012;18:25–33. https://doi.org/10.1111/j.1365-2516.2011.02573.x
Street AM, Ljung R, Lavery SA. Management of carriers and babies with haemophilia. Haemophilia 2008;14 Suppl 3:181–7. https://doi.org/10.1111/j.1365-2516.2008.01721.x
Abdul‐Kadir R, Davies J, Halimeh S, Chi C. Advances in pregnancy management in carriers of hemophilia. J Appl Hematol 2013;4:125. https://doi.org/10.4103/1658-5127.127894
Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII‐deficient women. Blood 2005;105:3382. https://doi.org/10.1182/blood-2004-11-4472
Knöfler R, Koscielny J, Tauer JT, Huhn B, Gneuss A, Kuhlisch E, et al. Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey. Hamostaseologie 2012;32:271–5. https://doi.org/10.5482/HAMO-12-06-0012
Dunkley SM, Russell SJ, Rowell JA, Barnes CD, Baker RI, Sarson MI, et al. A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. Med J Aust 2009;191:460–3.
Grootscholten K, Kok M, Oei SG, Mol BW, van der Post JA. External cephalic version‐related risks: a meta‐analysis. Obstet Gynecol 2008;112:1143–51. https://doi.org/10.1097/AOG.0b013e31818b4ade
Kok M, Cnossen J, Gravendeel L, van der Post J, Opmeer B, Mol BW. Clinical factors to predict the outcome of external cephalic version: a metaanalysis. Am J Obstet Gynecol 2008;199:630.e1–7; discussion e1–5. https://doi.org/10.1016/j.ajog.2008.03.008
Altisent C, Martorell M, Vidal F, Sánchez MA, Parra R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant: further considerations. Haemophilia 2011;17:818–9. https://doi.org/10.1111/j.1365-2516.2011.02505.x
Ljung R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery. Haemophilia 2010;16:415–9. https://doi.org/10.1111/j.1365-2516.2009.02144.x
Madan B, Street AM. What is the optimal mode of delivery for the haemophilia carrier expecting an affected infant‐vaginal delivery or caesarean delivery? Haemophilia 2010;16:425–6. https://doi.org/10.1111/j.1365-2516.2010.02238.x
James AH, Hoots K. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery. Haemophilia 2010;16:420–4. https://doi.org/10.1111/j.1365-2516.2009.02142.x
Ljung R, Lindgren AC, Petrini P, Tengborn L. Normal vaginal delivery is to be recommended for hemophilia carrier gravidae. Acta Paediatr 1994;83:609–11. https://doi.org/10.1111/j.1651-2227.1994.tb13090.x
Nazir HF, Al Lawati T, Beshlawi I, AlSharidah S, Elshinawy M, Alkasim F, et al. Mode of delivery and risk of intracranial haemorrhage in newborns with severe haemophilia A: a multicentre study in Gulf region. Haemophilia 2016;22:e134–8. https://doi.org/10.1111/hae.12842
Kletzel M, Miller CH, Becton DL, Chadduck WM, Elser JM. Postdelivery head bleeding in hemophilic neonates. Causes and management. Am J Dis Child 1989;143:1107–10. https://doi.org/10.1001/archpedi.1989.02150210143035
Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997;104:803–10. https://doi.org/10.1111/j.1471-0528.1997.tb12024.x
Royal College of Obstetricians and Gynaecologists. Caesarean Section. Consent Advice No. 7. London: RCOG; 2009
Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol 2011;205:262.e1–8. https://doi.org/10.1016/j.ajog.2011.06.035
Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ 2008;336:85–7. https://doi.org/10.1136/bmj.39405.539282.BE
Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995;102:101–6. https://doi.org/10.1111/j.1471-0528.1995.tb09060.x
Smith GC, Wood AM, White IR, Pell JP, Cameron AD, Dobbie R. Neonatal respiratory morbidity at term and the risk of childhood asthma. Arch Dis Child 2004;89:956–60. https://doi.org/10.1136/adc.2003.045971
Boulvain M, Marcoux S, Bureau M, Fortier M, Fraser W. Risks of induction of labour in uncomplicated term pregnancies. Paediatr Perinat Epidemiol 2001;15:131–8. https://doi.org/10.1046/j.1365-3016.2001.00337.x
Arrowsmith S, Wray S, Quenby S. Maternal obesity and labour complications following induction of labour in prolonged pregnancy. BJOG 2011;118:578–88. https://doi.org/10.1111/j.1471-0528.2010.02889.x
Modanlou H, Smith E, Paul RH, Hon EH. Complications of fetal blood sampling during labor. The pediatrician should always be informed when scalp samples have been taken. Clin Pediatr (Phila) 1973;12:603–6. https://doi.org/10.1177/000992287301201109
Sabir H, Stannigel H, Schwarz A, Hoehn T. Perinatal hemorrhagic shock after fetal scalp blood sampling. Obstet Gynecol 2010;115:419–20. https://doi.org/10.1097/AOG.0b013e3181c51aeb
Cheng YW, Hopkins LM, Caughey AB. How long is too long: does a prolonged second stage of labor in nulliparous women affect maternal and neonatal outcomes? Am J Obstet Gynecol 2004;191:933–8. https://doi.org/10.1016/j.ajog.2004.05.044
Gilad O, Merlob P, Stahl B, Klinger G. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med 2014;9:407–10. https://doi.org/10.1089/bfm.2014.0027
Cook TM, Counsell D, Wildsmith JA; Royal College of Anaesthetists Third National Audit Project. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009;102:179–90. https://doi.org/10.1093/bja/aen360
Ruppen W, Derry S, McQuay HJ, Moore RA. Incidence of epidural haematoma and neurological injury in cardiovascular patients with epidural analgesia/anaesthesia: systematic review and meta‐analysis. BMC Anesthesiol 2006;6:10. https://doi.org/10.1186/1471-2253-6-10
Choi S, Brull R. Neuraxial techniques in obstetric and non‐obstetric patients with common bleeding diatheses. Anesth Analg 2009;109:648–60. https://doi.org/10.1213/ane.0b013e3181ac13d1
Regional anaesthesia and patients with abnormalities of coagulation. Anaesthesia 2013;68:966–72. https://doi.org/10.1111/anae.12359
Evans D, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. Br Med J 1990;300:1694–5. https://doi.org/10.1136/bmj.300.6741.1694-a
Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2015;(6):CD007872. https://doi.org/10.1002/14651858.CD007872.pub3
Sentilhes L, Lasocki S, Ducloy‐Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, et al. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth 2015;114:576–87. https://doi.org/10.1093/bja/aeu448
Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 2011;12:503–16. https://doi.org/10.1517/14656566.2011.545818
Stoof SC, van Steenbergen HW, Zwagemaker A, Sanders YV, Cannegieter SC, Duvekot JJ, et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia 2015;21:505–12. https://doi.org/10.1111/hae.12635
Royal College of Obstetricians and Gynaecologists. Prevention and Management of Postpartum Haemorrhage. Green‐top Guideline No. 52. London: RCOG; 2009
Chi C, Shiltagh N, Kingman CE, Economides DL, Lee CA, Kadir RA. Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom. Haemophilia 2006;12:405–12. https://doi.org/10.1111/j.1365-2516.2006.01282.x
Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women with or without inherited bleeding disorders. Am J Obstet Gynecol 2010;203:56.e1–5. https://doi.org/10.1016/j.ajog.2010.02.042
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651–7.
Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001;112:264–74. https://doi.org/10.1046/j.1365-2141.2001.02362.x
Jørgensen FS, Felding P, Vinther S, Andersen GE. Vitamin K to neonates. Peroral versus intramuscular administration. Acta Paediatr Scand 1991;80:304–7. https://doi.org/10.1111/j.1651-2227.1991.tb11853.x
Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–74. https://doi.org/10.1055/s-0037-1613992
Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015;125:2029–37. https://doi.org/10.1182/blood-2014-08-528398
Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014;167:453–65. https://doi.org/10.1111/bjh.13064
Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006;4:774–82. https://doi.org/10.1111/j.1538-7836.2006.01823.x
James PD, Paterson AD, Notley C, Cameron C, Hegadorn C, Tinlin S, et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006;4:783–92. https://doi.org/10.1111/j.1538-7836.2006.01860.x
Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM‐1VWD). Blood 2007;109:112–21. Erratum 2008;111:3299–300. https://doi.org/10.1182/blood-2006-05-020784
Ranger A, Manning RA, Lyall H, Laffan MA, Millar CM. Pregnancy in type 2B VWD: a case series. Haemophilia 2012;18:406–12. https://doi.org/10.1111/j.1365-2516.2011.02691.x
Biguzzi E, Siboni SM, Ossola MW, Zaina B, Migliorini AC, Peyvandi F. Management of pregnancy in type 2B von Willebrand disease: case report and literature overview. Haemophilia 2015;21:e98–103. https://doi.org/10.1111/hae.12580
Kasatkar P, Shetty S, Ghosh K. Prenatal diagnosis in severe von Willebrand disease families from India using combination of phenotypic and genotypic assays. Prenat Diagn 2014;34:377–81. https://doi.org/10.1002/pd.4315
Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176–82.
Ramasahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995;1:140–4. https://doi.org/10.1111/j.1365-2516.1995.tb00056.x
Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986;68:282–5.
Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998;105:314–21. https://doi.org/10.1111/j.1471-0528.1998.tb10093.x
Huq FY, Kulkarni A, Agbim EC, Riddell A, Tuddenham E, Kadir RA. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia 2012;18:241–5. https://doi.org/10.1111/j.1365-2516.2011.02625.x
Sánchez‐Luceros A, Meschengieser SS, Marchese C, Votta R, Casais P, Woods AI, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003;14:647–51. https://doi.org/10.1097/01.mbc.0000061368.39736.71
Mahieu B, Jacobs N, Mahieu S, Naelaerts K, Vertessen F, Weyler J, et al. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul Fibrinolysis 2007;18:685–8. https://doi.org/10.1097/MBC.0b013e3282f09835
Kjellberg U, Andersson NE, Rosén S, Tengborn L, Hellgren M. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003;14:647–51.
James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007;5:1165–9. https://doi.org/10.1111/j.1538-7836.2007.02563.x
Andrew M, Paes B, Milner R, Johnson M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full‐term infant. Blood 1987;70:165–72.
Labarque V, Stain AM, Blanchette V, Kahr WH, Carcao MD. Intracranial haemorrhage in von Willebrand disease: a report of six cases. Haemophilia 2013;19:602–6. https://doi.org/10.1111/hae.12142
Chalmers E, Alamelu J, Collins P, Mathias M, Payne J, Richards M, et al. on behalf of the Paediatric and Rare Disorders Working Parties of UKHCDO. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003–2013. J Thromb Haemost 2015;13 Suppl 2:243. https://doi.org/10.1111/hae.13461
Sanders YV, Giezenaar MA, Laros‐van Gorkom BA, Meijer K, van der Bom JG, Cnossen MH, et al.; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014;12:1066–75. https://doi.org/10.1111/jth.12586
Rodegheiro F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al.; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardised questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010;8:2063–5. https://doi.org/10.1111/j.1538-7836.2010.03975.x
Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost 2012;10:2223–9. https://doi.org/10.1111/j.1538-7836.2012.04923.x
Chen YC, Chao TY, Cheng SN, Hu SH, Lius JY. Prevalence of von Willebrand disease in women with iron deficiency anaemia and menorrhagia in Taiwan. Haemophilia 2008;14:768–74. https://doi.org/10.1111/j.1365-2516.2008.01777.x
Rae C, Furlong W, Horsman J, Pullenayegum E, Demers C, St‐Louis J, et al. Bleeding disorders, menorrhagia and iron deficiency: impacts on health‐related quality of life. Haemophilia 2013;19:385–91. ВАШ ТЕКСТ
Leone G, Moneta E, Paparatti G, Boni P. Letter: Von Willebrand's disease in pregnancy. N Engl J Med 1975;293:456. https://doi.org/10.1056/NEJM197508282930918
Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica 2010;95:963–9. https://doi.org/10.3324/haematol.2009.011239
Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998;53:450–5.
Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989;74:1997–2000.
Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006;4:2164–9. https://doi.org/10.1111/j.1538-7836.2006.02070.x
Holmberg L, Nilsson IM, Borge L, Gunnarson M, Sjörin E. Platelet aggregation induced by 1‐desamino‐8‐D‐arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983;309:816–21. https://doi.org/10.1056/NEJM198310063091402
Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988;318:121. https://doi.org/10.1056/NEJM198801143180215
Bymes JJ, Lacarda A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988;28:63–5. https://doi.org/10.1002/ajh.2830280115
Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87–93. https://doi.org/10.1111/j.1365-2141.1992.tb04598.x
Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP VWF concentrate: the French experience. Haemophilia 1998;4Suppl 3:48–52. https://doi.org/10.1046/j.1365-2516.1998.0040s3048.x
Borel‐Derlon A, Federici AB, Roussel‐Robert V, Goudemand J, Lee CA, Scharrer I, et al. Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115–24. https://doi.org/10.1111/j.1538-7836.2007.02562.x
Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009;113:526–34. https://doi.org/10.1182/blood-2008-04-152280
Nichols WL, Hultin MB, James AH, Manco‐Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171–232. https://doi.org/10.1111/j.1365-2516.2007.01643.x
Chi C, Lee CA, England A, Hingorani J, Paintsil J, Kadir RA. Obstetric analgesia and anaesthesia in women with inherited bleeding disorders. Thromb Haemost 2009;101:1104–11. https://doi.org/10.1160/TH08-10-0694
Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973;238:1–159.
Cyklo‐f 500 mg film coated tablets. Accessed 2015 Oct 7. www.medicines.org.uk/emc/medicine/27753
Faculty of Sexual and Reproductive Healthcare. Clinical Guidance. Contraception After Pregnancy. London: FSRH; 2017.
Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52. https://doi.org/10.1182/blood-2004-02-0595
Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167:304–26. https://doi.org/10.1111/bjh.13058
Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002;8:308–21. https://doi.org/10.1046/j.1365-2516.2002.00633.x
Seligsohn U. Factor XI deficiency. Thromb Haemost 1993;70:68–71.
Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978;51:1223–8.
Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995;85:429–32.
Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990;63:36–8.
Bolton‐Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI‐deficient kindreds‐‐a clinical and laboratory study. Thromb Haemost 1995;73:194–202.
Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin‐mediated activation of factor XI results in a thrombin‐activatable fibrinolysis inhibitor‐dependent inhibition of fibrinolysis. J Clin Invest 1997;99:2323–7. https://doi.org/10.1172/JCI119412
Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012;10:615–21. https://doi.org/10.1111/j.1538-7836.2012.04653.x
Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006;12:490–3. https://doi.org/10.1111/j.1365-2516.2006.01304.x
Bolton‐Maggs PH, Young Wan‐Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988;69:521–8. https://doi.org/10.1111/j.1365-2141.1988.tb02409.x
Bolton‐Maggs PH. Factor XI deficiency–resolving the enigma? Hematology Am Soc Hematol Educ Program 2009;1:97–105. https://doi.org/10.1182/asheducation-2009.1.97
Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynecol Obstet Invest 1981;12:141–54. https://doi.org/10.1159/000299596
Myers B, Pavord S, Kean L, Hill M, Dolan G. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG 2007;114:643–6. https://doi.org/10.1111/j.1471-0528.2007.01296.x
Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005;16:37–41.
Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009;88:1095–100. https://doi.org/10.1080/00016340903144238
Myers B, Neal R, Curry N, Kadir R, Pavord S. Blood group, bleeding phenotype and post‐partum haemorrhage in factor XI‐deficient women. International Society on Thrombosis and Haemostasis 2015 Congress, 20–25 June 2015, Toronto, Canada. Poster 175. https://doi.org/10.1111/jth.12993
Bolton‐Maggs PH, Colvin BT, Satchi G, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994;344:748–9. https://doi.org/10.1016/S0140-6736(94)92237-3
Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994;84:1314–9.
Bolton‐Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P. FXI concentrate use and the risk of thrombosis. Haemophilia 2014;20:e349–51. https://doi.org/10.1111/hae.12457
Riddell A, Abdul‐Kadir R, Pollard D, Tuddenham E, Gomez K. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost 2011;106:521–7. https://doi.org/10.1160/TH10-12-0816
Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003;101:4783–8. https://doi.org/10.1182/blood-2002-09-2794
Livnat T, Tamarin I, Mor Y, Winckler H, Horowitz Z, Korianski Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI‐deficient patients with inhibitor antibodies. Thromb Haemost 2009;102:487–92. https://doi.org/10.1160/TH09-03-0172
Ginsberg SS, Clyne LP, McPhedran P, Duffy TP, Hanson T. Successful childbirth by a patient with congenital factor XI deficiency and an acquired inhibitor. Br J Haematol 1993;84:172–4. https://doi.org/10.1111/j.1365-2141.1993.tb03044.x
Bolton–Maggs PH. Treatment of Hemophilia: Factor XI deficiency and its management. 3rd ed. Montréal, Québec: World Federation of Hemophilia; 2008. Accessed 2016 Jul 26. www.exodontia.info/files/Treatment_of_H_mophilia_2008._Factor_XI_Deficiency_Its_Management.pdf
O'Connell NM, Pascoe GM, Riddell AR, Brown SA, Perry DJ, Lee CA. Prevention of surgical bleeding with recombinant factor VIIa in patients with factor XI deficiency. Blood 2002;100:697a.
Lee CA, Chi C, Pavord SR, Bolton‐Maggs PH, Pollard DA, Hinchcliffe‐Wood A, et al. The obstetric and gynaecological management of women with inherited bleeding disorders‐‐review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006;12:301–36. https://doi.org/10.1111/j.1365-2516.2006.01314.x
Singh A, Harnett MJ, Connors JM, Camann WR. Factor XI deficiency and obstetrical anesthesia. Anesth Analg 2009;108:1882–5. https://doi.org/10.1213/ane.0b013e3181a28715
Reuveni A, Orbach‐Zinger S, Eidelman LA, Ginosar Y, Ioscovich A. Peripartum anesthetic management of patients with Factor XI deficiency. J Perinat Med 2013;42:295–300. https://doi.org/10.1515/jpm-2013-0144
Bolton‐Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders‐‐review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004;10:593–628. https://doi.org/10.1111/j.1365-2516.2004.00944.x
Herrmann FH, Auerswald G, Ruiz‐Saez A, Navarrete M, Pollmann H, Lopaciuk S, et al.; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006;12:479–89. https://doi.org/10.1111/j.1365-2516.2006.01303.x
Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015;125:2052–61. https://doi.org/10.1182/blood-2014-08-532820
Acharya SS, Coughlin A, Dimichele DM; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248–56. https://doi.org/10.1111/j.1538-7836.2003.t01-1-00553.x
Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H, et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010;95:956–62. https://doi.org/10.3324/haematol.2009.017210
Kulkarni AA, Lee CA, Kadir RA. Pregnancy in women with congenital factor VII deficiency. Haemophilia 2006;12:413–6. https://doi.org/10.1111/j.1365-2516.2006.01287.x
Konje JC, Murphy P, de Chazal R, Davidson A, Taylor D. Severe factor X deficiency and successful pregnancy. Br J Obstet Gynaecol 1994;101:910–1. https://doi.org/10.1111/j.1471-0528.1994.tb13557.x
Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre‐eclampsia. Br J Obstet Gynaecol 1976;83:636–9. https://doi.org/10.1111/j.1471-0528.1976.tb00902.x
Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013;19:e349–57. https://doi.org/10.1111/hae.12259
Tran HT, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2014;20:369–75. https://doi.org/10.1111/hae.12318
Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al.; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005;93:481–7. https://doi.org/10.1160/TH04-10-0650
Catanzarite VA, Novotny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol 1997;14:135–8. https://doi.org/10.1055/s-2007-994113
Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999;82:1207–14. https://doi.org/10.1055/s-0037-1614361
Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998;103:1067–9. https://doi.org/10.1046/j.1365-2141.1998.01077.x
Noia G, De Carolis S, De Stefano V, Ferrazzani S, De Santis L, Carducci B, et al. Factor V deficiency in pregnancy complicated by Rh immunization and placenta previa. A case report and review of the literature. Acta Obstet Gynecol Scand 1997;76:890–2. https://doi.org/10.3109/00016349709024374
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008;14:671–84. https://doi.org/10.1111/j.1365-2516.2008.01695.x
Girolami A, Scandellari R, Lombardi AM, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia 2005;11:26–30. https://doi.org/10.1111/j.1365-2516.2005.01056.x
Coppola A, Maruotti GM, Feola G, Catalano A, Quaglia F, Tomaiuolo M, et al. Management of patients with factor V deficiency: open issues from the challenging history of a woman with anaphylactic transfusion reactions. Haemophilia 2010;16:560–3. https://doi.org/10.1111/j.1365-2516.2009.02147.x
Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001;7 Suppl 1:16–22. https://doi.org/10.1046/j.1365-2516.2001.00100.x
Herrmann FH, Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, et al.; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009;15:267–80. https://doi.org/10.1111/j.1365-2516.2008.01910.x
Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, et al.; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009;7:774–9. https://doi.org/10.1111/j.1538-7836.2009.03329.x
Di Minno MN, Dolce A, Mariani G; STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013;109:1051–9. https://doi.org/10.1160/TH12-10-0740
Fadel HE, Krauss JS. Factor VII deficiency and pregnancy. Obstet Gynecol 1989;73:453–4. https://doi.org/10.1016/0020-7292(89)90244-0
Kadir R, Chi C, Bolton‐Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009;15:990–1005. https://doi.org/10.1111/j.1365-2516.2009.01984.x
Baumann Kreuziger LM, Morton CT, Reding MT. Is prophylaxis required for delivery in women with factor VII deficiency? Haemophilia 2013;19:827–32. https://doi.org/10.1111/hae.12167
Girolami A, Randi ML, Ruzzon E, Lombardi AM, Girolami B, Fabris F. Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K‐dependent coagulation factors. Acta Haematol 2006;115:58–63. https://doi.org/10.1159/000089467
Nance D, Josephson NC, Paulyson‐Nunez K, James AH. Factor X deficiency and pregnancy: preconception counselling and therapeutic options. Haemophilia 2012;18:e277–85. https://doi.org/10.1111/j.1365-2516.2011.02724.x
Kumar M, Mehta P. Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X‐deficient woman. Am J Hematol 1994;46:241–4. https://doi.org/10.1002/ajh.2830460315
Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000;55:103–8.
Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open‐label study. Thromb Res 2012;130 Suppl 2:S12–4. https://doi.org/10.1016/S0049-3848(13)70005-7
Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012;119:5111–7. https://doi.org/10.1182/blood-2011-10-386045
Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007;62:255–60. https://doi.org/10.1097/01.ogx.0000259176.03156.2b
Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999;107:468–84. https://doi.org/10.1046/j.1365-2141.1999.01648.x
Mannucci PM. Bleeding symptoms in heterozygous factor XIII [corrected] deficiency. Haematologica 2010;95:e6. https://doi.org/10.3324/haematol.2010.028969
Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non‐Ashkenazi Jews. N Engl J Med 1982;307:1191–5. https://doi.org/10.1056/NEJM198211043071907
Peyvandi F, Tuddenham EG, Akhtari AM, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998;100:773–6. https://doi.org/10.1046/j.1365-2141.1998.00620.x
Oukkache B, El Graoui O, Zafad S. Combined factor V and VIII deficiency and pregnancy. Int J Hematol 2012;96:786–8. https://doi.org/10.1007/s12185-012-1201-z
Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999;107:204–6. https://doi.org/10.1046/j.1365-2141.1999.01681.x
Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006;4:1634–7. https://doi.org/10.1111/j.1538-7836.2006.02014.x
Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151–61.
Miesbach W, Scharrer I, Henschen A, Neerman‐Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010;21:35–40. https://doi.org/10.1097/MBC.0b013e328331e6db
de Moerloose P, Casini A, Neerman‐Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39:585–95. https://doi.org/10.1055/s-0033-1349222
Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013;160:220–7. https://doi.org/10.1111/bjh.12085
Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989;44:157–61.
Yamanaka Y, Takeuchi K, Sugimoto M, Sato A, Nakago S, Maruo T. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003;82:972–3. https://doi.org/10.1034/j.1600-0412.2003.00211.x
Roqué H, Stephenson C, Lee MJ, Funai EF, Popiolek D, Kim E, et al. Pregnancy‐related thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol 2004;76:267–70. https://doi.org/10.1002/ajh.20110
Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco‐Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011;9:1687–704. https://doi.org/10.1111/j.1538-7836.2011.04424.x
Mensah P, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia 2011;17:167–8. https://doi.org/10.1111/j.1365-2516.2010.02363.x
Munoz J, Schering J, Lambing A, Neal S, Goyert G, Green PM, et al. The dilemma of inherited dysfibrinogenemia during pregnancy. Blood Coagul Fibrinolysis 2012;23:775–7. https://doi.org/10.1097/MBC.0b013e328358e96d
Franchini M, Raffaelli R, Musola M, Memmo A, Poli G, Franchi M, et al. Management of inherited dysfibrinogenemia during pregnancy: a description of four consecutive cases. Ann Hematol 2007;86:693–4. https://doi.org/10.1007/s00277-007-0307-5
López JA, Andrews RK, Afshar‐Kharghan V, Berndt MC. Bernard‐Soulier syndrome. Blood 1998;91:4397–418.
Prabu P, Parapia LA. Bernard‐Soulier syndrome in pregnancy. Clin Lab Haematol 2006;28:198–201. https://doi.org/10.1111/j.1365-2257.2006.00780.x
Bolton‐Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Leisner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–33. https://doi.org/10.1111/j.1365-2141.2006.06343.x
Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard‐Soulier syndrome. Int J Hematol 2002;76:319–27. https://doi.org/10.1007/BF02982690
Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011;155:30–44. https://doi.org/10.1111/j.1365-2141.2011.08793.x
Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010;16:584–91. https://doi.org/10.1111/j.1365-2516.2009.02137.x
Michalas S, Malamitsi‐Puchner A, Tsevrenis H. Pregnancy and delivery in Bernard‐Soulier syndrome. Acta Obstet Gynecol Scand 1984;63:185–6. https://doi.org/10.3109/00016348409154659
Heslop HE, Hickton CM, Laird E, Tait JD, Doig JR, Beard EJ. Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. Scand J Haematol 1986;37:71–3. https://doi.org/10.1111/j.1600-0609.1986.tb01774.x
Zafar S, Sultana S, Iqbal W, Bhatti FA, Khanam Akhtar KA, Muhammed A, et al. Pregnancy Outcome in Bernard‐Soulier Syndrome Complicated by Preeclampsia. J Turk Ger Gynecol Assoc 2007;8:324–6.
Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427–38. https://doi.org/10.1016/S0140-6736(07)61198-2
Waldenström E, Holmberg L, Axelsson U, Winqvist I, Nilsson IM. Bernard‐Soulier syndrome in two Swedish families: effect of DDAVP on bleeding time. Eur J Haematol 1991;46:182–7. https://doi.org/10.1111/j.1600-0609.1991.tb01274.x
Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002;87:1122–4.
Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011;17:e858–69. https://doi.org/10.1111/j.1365-2516.2011.02516.x
Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858–64. https://doi.org/10.1182/blood-2004-06-2223
Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 2008;14 Suppl 1:31–9. https://doi.org/10.1111/j.1365-2516.2007.01607.x
Santoro C, Rago A, Biondo F, Conti L, Pulcinelli F, Laurenti L, et al. Prevalence of allo‐immunization anti‐HLA and anti‐integrin alphaIIbbeta3 in Glanzmann Thrombasthenia patients. Haemophilia 2010;16:805–12. https://doi.org/10.1111/j.1365-2516.2010.02230.x
Ghevaert C, Campbell K, Stafford P, Metcalfe P, Casbard A, Smith GA, et al. HPA‐1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion 2007;47:1296–305. https://doi.org/10.1111/j.1537-2995.2007.01273.x
Killie MK, Husebekk A, Kaplan C, Taaning E, Skogen B. Maternal human platelet antigen‐1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 2007;47:55–8. https://doi.org/10.1111/j.1537-2995.2007.01063.x
Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001;185:683–8. https://doi.org/10.1067/mob.2001.116727
Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011;118:1157–63. https://doi.org/10.1097/AOG.0b013e31823403f4
Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011; (5):CD004226. https://doi.org/10.1002/14651858.CD004226.pub2
Seligsohn U, Mibashan RS, Rodeck CH, Nicolaides KH, Millar DS, Coller BS. Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet 1985;28:1419. https://doi.org/10.1016/S0140-6736(85)92579-6
French DL, Coller BS, Usher S, Berkowitz R, Eng C, Seligsohn U, et al. Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. Br J Haematol 1998;102:582–7. https://doi.org/10.1046/j.1365-2141.1998.00798.x
Srivastava A, Usher S, Nelson EJ, Jayandharan G, Shaji RV, Chandy M, et al. Prenatal diagnosis of Glanzmann thrombasthenia. Natl Med J India 2003;16:207–8.
van der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang 2013;105:236–43. https://doi.org/10.1111/vox.12036
Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010;149:813–23. https://doi.org/10.1111/j.1365-2141.2010.08191.x
Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell‐free fetal DNA: a systematic review and meta‐analysis. JAMA 2011;306:627–36. https://doi.org/10.1001/jama.2011.1114
